NCT04119024 - Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUveal MelanomaAcral MelanomaNeuroendocrine TumorsParagangliomaPheochromocytomaAdrenocortical CarcinomaPancreatic Neuroendocrine TumorThyroid CancerBreast CancerLung AdenocarcinomaHead and Neck Squamous Cell Carcinoma

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Fludeoxyglucose F-18

Undergo FDG-PET/CT scan

BIOLOGICAL

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET scan

Trial Locations (2)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

93405

RECRUITING

Stanford Cancer Institute, Stanford